Aberdeen Group
SNDX icon

Aberdeen Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Aberdeen Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.15M Buy
372,766
+85,797
+30% +$1.78M 0.01% 637
2026
Q1 		$6.7M Sell
286,969
-85,823
-23% -$1.86M 0.01% 657
2025
Q4 		$7.83M Hold
372,792
– – 0.01% 647
2025
Q3 		$5.74M Buy
372,792
+69,366
+23% +$908K 0.01% 687
2025
Q2 		$2.84M Buy
303,426
+170,993
+129% +$1.88M ﹤0.01% 757
2025
Q1 		$1.63M Buy
132,433
+33,093
+33% +$467K ﹤0.01% 777
2024
Q4 		$1.31M Buy
+99,340
New +$1.7M ﹤0.01% 800
2021
Q4 		– Sell
-14,248
Closed -$272K – 1068
2021
Q3 		$272K Buy
+14,248
New +$237K ﹤0.01% 1010

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Aberdeen Group's SNDX Position: Q2 2026 in Review

Aberdeen Group increased its Syndax Pharmaceuticals (SNDX) stake by 30% in Q2 2026, buying an estimated $1.78M and bringing the position to 372,766 shares worth $8.15M. The position accounts for 0.01% of the portfolio, ranked #637.

Aberdeen Group first reported a position in SNDX in Q3 2021 and has held it in 8 quarters since. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Aberdeen Group held 372,766 shares of Syndax Pharmaceuticals worth $8.15M as of Q2 2026.
  • Aberdeen Group bought 85,797 Syndax Pharmaceuticals shares in Q2 2026, an estimated $1.78M.
  • Syndax Pharmaceuticals made up 0.01% of Aberdeen Group's portfolio in Q2 2026, its #637 holding.
  • Aberdeen Group first reported a position in Syndax Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.